6 Most Promising Corona Vaccines

Scientists worldwide are developing scores of novel vaccine candidates to combat the novel coronavirus, using resources ranging from compromised cold viruses to fragments of genetic code — and they're doing so at breakneck speed. It is unknown when the virus jumped from animals to humans and when it began to spread across territories. Here is the list of the Most Promising Vaccines for COVID-19, and help us come out of the pandemic.

Posted On April 27th, 2021

Oxford AstraZeneca

The Oxford-AstraZeneca COVID-19 vaccine, also known as Vaxzevria as of March 25, 2021, is a two-dose vaccine developed in collaboration with the Oxford Vaccine Group and pharmaceutical firm AstraZeneca to target the SARS-CoV-2 virus. The Serum Institute of India's COVID-19 vaccine, known as Covishield, is a localized variant of the Oxford-AstraZeneca vaccine. The vaccine has a 76 percent efficacy rate after both doses, according to AstraZeneca's primary review of phase 3 trial results.

Johnson and Johnson

In clinical trials, the J&J/Janssen vaccine was 66.3 percent successful at reducing laboratory-confirmed COVID-19 disease in people who had no signs of previous infection 2 weeks after getting the vaccine (efficacy). People were best protected two weeks after being vaccinated. Among patients who did get ill, the vaccine has high effectiveness in reducing hospitalization and mortality. No one who contracted COVID-19 at least four weeks after receiving the J&J/Janssen vaccine needed hospitalization.

Novavax

The Novavax COVID-19 vaccine, also known as SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate created by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI) that is currently being tested in India under the brand name Covovax. Its protein-based COVID-19 vaccine candidate reached the primary goal, with a vaccine efficacy of 89.3 percent, in its clinical trials.

Sinovac

Sinovac, a Beijing-based biopharmaceutical firm, is the company behind CoronaVac, an inactivated vaccine. It works by exposing the body's immune system to the virus through killed viral particles without risking a severe disease response. In a group of Brazilian healthcare staff, the Sinovac COVID-19 vaccine was found to be 50% safe.

Pfizer

The Pfizer-BioNTech COVID-19 vaccine is an mRNA-based COVID-19 vaccine marketed under the brand name Community. The vaccine's manufacturer, the German company BioNTech, collaborated with the American company Pfizer on clinical testing, logistics, and manufacturing. According to scientists, the vaccine has a high effectiveness score of more than 90%.

Sputnik V

The Gamaleya Research Institute of Epidemiology and Microbiology developed Sputnik V, a viral vector vaccine for COVID-19. Sputnik V is a vaccine based on an adenovirus viral vector. Russia's first COVID-19 vaccine, which was also the first to be approved for use in August, has an impressive efficacy rate of more than 92 percent. Limited clinical trials, according to experts, have shown that the vaccine had a healthy immunogenicity reaction.